Haemonetics (HAE) to Release Earnings on Thursday

Haemonetics (NYSE:HAE) is expected to be posting its Q2 2026 results before the market opens on Thursday, November 6th. Analysts expect Haemonetics to post earnings of $1.12 per share and revenue of $311.6080 million for the quarter. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS.Individuals are encouraged to explore the company’s upcoming Q2 2026 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, beating the consensus estimate of $1.01 by $0.09. The firm had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The business’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.02 earnings per share. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $49.38 on Thursday. The firm has a market cap of $2.38 billion, a P/E ratio of 15.10, a P/E/G ratio of 0.93 and a beta of 0.37. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. Haemonetics has a 12 month low of $47.31 and a 12 month high of $94.99. The stock’s fifty day moving average price is $51.48 and its 200-day moving average price is $62.24.

Hedge Funds Weigh In On Haemonetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC grew its stake in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the last quarter. Strs Ohio purchased a new stake in shares of Haemonetics during the first quarter worth about $140,000. Sivia Capital Partners LLC purchased a new stake in shares of Haemonetics during the second quarter worth about $234,000. United Services Automobile Association purchased a new stake in shares of Haemonetics during the first quarter worth about $212,000. Finally, Caxton Associates LLP purchased a new stake in shares of Haemonetics during the first quarter worth about $216,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

HAE has been the topic of several research reports. Raymond James Financial lowered Haemonetics from a “strong-buy” rating to an “outperform” rating and cut their price target for the company from $105.00 to $78.00 in a research note on Monday, August 11th. Needham & Company LLC restated a “buy” rating and set a $68.00 price target (down previously from $84.00) on shares of Haemonetics in a research note on Thursday, August 7th. JPMorgan Chase & Co. restated a “neutral” rating and set a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Mizuho cut their price target on Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Friday, August 8th. Finally, Citigroup cut their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.